Inactivation of heparin by cationically modified chitosan

Marine Drugs

Volumn 12, Issue 7, 2014, Pages 3953-3969

  Lorkowska Zawicka, Barbara ^a   Kamiński, Kamil ^b   Ciejka, Justyna ^b   Szczubiałka, Krzysztof ^b   Białas, Magdalena ^a   Okoń, Krzysztof ^a   Adamek, Dariusz ^a   Nowakowska, Maria ^b   Jawień, Jacek ^a   Olszanecki, Rafał ^a   Korbut, Ryszard ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Chitosan; Coagulation; Heparin antidote; Hepatotoxicity; HTCC; Protamine; Unfractionated heparin

Indexed keywords

CHITOSAN; HEPARIN; N (2 HYDROXYPROPYL) 3 TRIMETHYLAMMONIUM CHITOSAN CHLORIDE; PROTAMINE; UNCLASSIFIED DRUG; HEPARIN ANTAGONIST;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INACTIVATION; DRUG POTENCY; DRUG SAFETY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; LIVER; PATHOLOGY; WISTAR RAT;

ANIMALS; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN ANTAGONISTS; LIVER; MALE; PARTIAL THROMBOPLASTIN TIME; RATS; RATS, WISTAR;

EID: 84905842819     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12073953     Document Type: Article

References (50)

1. Chang, L.C.; Liang, J.F.; Lee, H.F.; Lee, L.M.; Yang, V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity. AAPS Pharm. Sci. 2001, 3, 15-23.
2. Lever, R.; Mulloy, B.; Page, C.P. Heparin - A century of progress. Handb. Exp. Pharmacol. 2012, 207, 265-276.
3. Chandy, T.; Sharma, C.P. Chitosan - As a biomaterial. Biomater. Artif. Cells Artif. Organs 1990, 18, 1-24. (Pubitemid 20133629)
4. Kato, Y.; Onishi, H.; Machida, Y. Application of chitin and chitosan derivatives in the pharmaceutical field. Curr. Pharm. Biotechnol. 2003, 4, 303-309. (Pubitemid 37220862)
5. Ravi Kumar, M.N.V. A review of chitin and chitosan applications. React. Funct. Polym. 2000, 46, 1-27. (Pubitemid 33763425)
6. Van der Lubben, I.M.; Verhoef, J.C.; Borchard, G.; Junginger, H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14, 201-207. (Pubitemid 32884316)
7. Zhang, J.; Xia, W.; Liu, P.; Cheng, Q.; Tahirou, T.; Gu, W.; Li, B. Chitosan modification and pharmaceutical/biomedical applications. Mar. Drugs 2010, 8, 1962-1987.
8. Lee, J.K.; Kim, S.U.; Kim, J.H. Modification of chitosan to improve its hypocholesterolemic capacity. Biosci. Biotechnol. Biochem. 1999, 63, 833-839. (Pubitemid 129562757)
9. Pangestuti, R.; Kim, S.-K. Neuroprotective properties of chitosan and its derivatives. Mar. Drugs 2010, 8, 2117-2128.
10. Kamiński, K.; Szczubiałka, K.; Zazakowny, K.; Lach, R.; Nowakowska, M. Chitosan derivatives as novel potential heparin reversal agents. J. Med. Chem. 2010, 53, 4141-4147.
11. Kamiński, K.; Zazakowny, K.; Szczubiałka, K.; Nowakowska, M. pH-Sensitive genipin-cross-linked chitosan microspheres for heparin removal. Biomacromolecules 2008, 9, 3127-3132.
12. García-Manzano, A.; González-Llaven, J.; Lemini, C.; Rubio-Póo, C. Standardization of rat blood clotting tests with reagents used for humans. Proc. West. Pharmacol. Soc. 2001, 44, 153-155. (Pubitemid 34087743)
13. Lemini, C.; Jaimez, R.; Franco, Y. Gender and inter-species influence on coagulation tests of rats and mice. Thromb. Res. 2007, 120, 415-419. (Pubitemid 46881257)
14. Nam, K.-S.; Kim, M.-K.; Shon, Y.-H. Chemopreventive effect of chitosan oligosaccharide against colon carcinogenesis. J. Microbiol. Biotechnol. 2007, 17, 1546-1549. (Pubitemid 47577755)
15. Kean, T.; Thanou, M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62, 3-11.
16. Aranaz, I.; Mengibar, M.; Harris, R.; Panos, I.; Miralles, B.; Acosta, N.; Galed, G.; Heras, A. Functional characterisation of chitin and chitosan. Curr. Chem. Biol. 2009, 3, 203-230.
17. Niederhofer, A.; Müller, B.W. A method for direct preparation of chitosan with low molecular weight from fungi. Eur. J. Pharm. Biopharm. 2004, 57, 101-105. (Pubitemid 38058808)
18. Sashiwa, H.; Aiba, S. Chemically modified chitin and chitosan as biomaterials. Prog. Polym. Sci. 2004, 29, 887-908.
19. Lin, S.-B.; Lin, Y.-C.; Chen, H.-H. Low molecular weight chitosan prepared with the aid of cellulase, lysozyme and chitinase: Characterisation and antibacterial activity. Food Chem. 2009, 116, 47-53.
20. Lee, C.G. Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med. J. 2009, 50, 22-30.
21. Chou, T.-C.; Fu, E.; Wu, C.-J.; Yeh, J.-H. Chitosan enhances platelet adhesion and aggregation. Biochem. Biophys. Res. Commun. 2003, 302, 480-483. (Pubitemid 36279554)
22. Janvikul, W.; Uppanan, P.; Thavornyutikarn, B.; Krewraing, J.; Prateepasen, R. In vitro comparative hemostatic studies of chitin, chitosan, and their derivatives. J. Appl. Polym. Sci. 2006, 102, 445-451. (Pubitemid 44518443)
23. Okamoto, Y.; Yano, R.; Miyatake, K.; Tomohiro, I.; Shigemasa, Y.; Minami, S. Effects of chitin and chitosan on blood coagulation. Carbohydr. Polym. 2003, 53, 337-342.
24. Benesch, J.; Tengvall, P. Blood protein adsorption onto chitosan. Biomaterials 2002, 23, 2561-2568. (Pubitemid 34288496)
25. Lord, M.S.; Cheng, B.; McCarthy, S.J.; Jung, M.; Whitelock, J.M. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials 2011, 32, 6655-6662.
26. Dowling, M.B.; Kumar, R.; Keibler, M.A.; Hess, J.R.; Bochicchio, G.V.; Raghavan, S.R. A self-assembling hydrophobically modified chitosan capable of reversible hemostatic action. Biomaterials 2011, 32, 3351-3357.
27. Rao, S.B.; Sharma, C.P. Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 1997, 34, 21-28. (Pubitemid 26425214)
28. Yang, J.; Tian, F.; Wang, Z.; Wang, Q.; Zeng, Y.; Chen, S. Effect of chitosan molecular weight and deacetylation degree on hemostasis. J. Biomed. Mater. Res. Part B Appl. Biomater. 2008, 84B, 131-137.
29. Klokkevold, P.R.; Fukayama, H.; Sung, E.C.; Bertolami, C.N. The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. J. Oral Maxillofac. Surg. 1999, 57, 49-52. (Pubitemid 29024875)
30. Kurita, K. Controlled functionalization of the polysaccharide chitin. Prog. Polym. Sci. 2001, 26, 1921-1971. (Pubitemid 33089088)
31. Schipper, N.; Vårum, K.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 1996, 13, 1686-1692. (Pubitemid 26426893)
32. Richardson, S.C.; Kolbe, H.V.; Duncan, R. Potential of low molecular mass chitosan as a DNA delivery system: Biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm. 1999, 178, 231-243. (Pubitemid 29078577)
33. Omara, E.A.; Aly, H.F.; Nada, S.A. Chitosan induced hepato-nephrotoxicity in mice with special reference to gender effect in glycolytic enzymes activities. Regul. Toxicol. Pharmacol. 2012, 62, 29-40.
34. Loh, J.W.; Yeoh, G.; Saunders, M.; Lim, L.-Y. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol. Appl. Pharmacol. 2010, 249, 148-157.
35. Farouk, M.; Atiat, M.; Abd El-Rahman, M.; Ashraf, A.; Abd El-Karim, I. Effect of some drugs and herbs on experimental rats suffering from obesity. Res. J. Specif. Educ. 2011, 697-724.
36. Sethumadhavan Santhosh, T.K.S. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur. J. Pharmacol. 2007, 572, 69-73.
37. Zhou, G.-D.; Li, M.-R.; Zhang, J.; Pan, D.; Zhao, S.-X.; Yang, J.-F.; Yu, J.; Zhao, J.-M. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol. 2008, 43, 1371-1377.
38. Sobol, M.; Bartkowiak, A.; de Haan, B.; de Vos, P. Cytotoxicity study of novel water-soluble chitosan derivatives applied as membrane material of alginate microcapsules. J. Biomed. Mater. Res. A 2012, 100A, 1907-1914.
39. Tanaka, Y.; Tanioka, S.; Tanaka, M.; Tanigawa, T.; Kitamura, Y.; Minami, S.; Okamoto, Y.; Miyashita, M.; Nanno, M. Effects of chitin and chitosan particles on BALB/c mice by oral and parenteral administration. Biomaterials 1997, 18, 591-595. (Pubitemid 27186867)
40. Zwischenberger, J.B.; Vertrees, R.A.; Brunston, R.L., Jr.; Tao, W.; Alpard, S.K.; Brown, P.S., Jr. Application of a heparin removal device in patients with known protamine hypersensitivity. J. Thorac. Cardiovasc. Surg. 1998, 115, 729-731. (Pubitemid 28158095)
41. Kikura, M.; Lee, M.K.; Levy, J.H. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth. Analg. 1996, 83, 223-227. (Pubitemid 26255808)
42. Despotis, G.J.; Summerfield, A.L.; Joist, J.H.; Goodnough, L.T.; Santoro, S.A.; Zimmermann, J.J.; Lappas, D.G. In vitro reversal of heparin effect with heparinase: Evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth. Analg. 1994, 79, 670-674. (Pubitemid 24307144)
43. Stafford-Smith, M.; Lefrak, E.A.; Qazi, A.G.; Welsby, I.J.; Barber, L.; Hoeft, A.; Dorenbaum, A.; Mathias, J.; Rochon, J.J.; Newman, M.F. Efficacy and safety of heparinase I vs. protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005, 103, 229-240. (Pubitemid 41076719)
44. Dehmer, G.J.; Fisher, M.; Tate, D.A.; Teo, S.; Bonnem, E.M. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995, 91, 2188-2194.
45. Schick, B.P.; Maslow, D.; Moshinski, A.; San Antonio, J.D. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 2004, 103, 1356-1363. (Pubitemid 38168648)
46. Kurata, M.; Sasayama, Y.; Yamasaki, N.; Kitazawa, I.; Hamada, Y.; Horii, I. Mechanism for shortening PT and APTT in dogs and rats - effect of fibrinogen on PT and APTT. J. Toxicol. Sci. 2003, 28, 439-443. (Pubitemid 38133222)
47. Tabata, H.; Nakamura, S.; Matsuzawa, T. Some species differences in the false prolongation of prothrombin times and activated partial thromboplastin times in toxicology. Comp. Haematol. Int. 1995, 5, 140-144.
48. Dempfle, C.-E.; Borggrefe, M. Do we need thrombin generation assays for monitoring anticoagulation? Thromb. Haemost. 2008, 100, 179-180.
49. Nielsen, V.G. The detection of changes in heparin activity in the rabbit: A comparison of anti-xa activity, thrombelastography, activated partial thromboplastin time, and activated coagulation time. Anesth. Analg. 2002, 95, 1503-1506. (Pubitemid 35423932)
50. Fuller, J.; Woodman, D.D. Evaluation of a 2-stage automated coagulometer for multispecies studies. Lab. Anim. 1981, 15, 53-55. (Pubitemid 11185575)